Innovation Pharmaceuticals Inc (IPIX)

[TheHound]

Quote:
Kevetrin is a novel drug candidate targeting p53 in solid tumors like ovarian (Ph1) and Pancreatic Cancer, an area of critical unmet need where it has been granted an orphan drug status. As a targeted therapy, we expect its value to surge manifold in 2017 when Proof-of- Concept (PoC) will establish its value akin to the poly (ADP-ribose) polymerase enzyme (PARP) inhibitors (Peak sale potential $4 billion in Ovarian Cancer alone).

• Robust Patent estate: Intellectual Property protection of all its assets and several other novel compounds in the early stage of development.
• Expansion of the existing drug candidates in other new niche indications could amplify the commercial potential by several fold.
• An Able, Experienced Scientific, and Management Team has succeeded in developing a mature pipeline of novel drug candidates in a very cost effective way. Highly experienced in clinical trials / regulatory affairs and successful launch of innovative drugs.


http://cellceutix.com/cellceutix-prepares-phase-2a-ovarian-cancer-trial-of-kevetrin-a-novel-p53-modulating-drug-candidate-based-upon-phase-1-topline-data/

http://www.mpadvisor.com/xyz/Cellceutix_160826.pdf